CD37 and neoplasm: In addition, DuoHexaBody-CD37 showed significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, indicating that DuoHexaBody-CD37 may serve as a promising novel therapeutic antibody for treatment of human B-cell malignancies.